NAME POSITION INTERESTS DECLARED Dominic Chief Operating Wife is self-employed bid manager whose Hardisty Officer work includes writing bids for NHS and social care contract tenders for a variety of NHS, third sector and private sector providers. Very occasionally these might give rise to a conflict of interest relating to bids that the Trust intends making, in which case this would need to be specifically declared and appropriate arrangements made. Date: 21 June 2016 NAME POSITION INTERESTS DECLARED Martin Chair Governor Oxford Brookes University – Howell Governor Oxford University Hospitals NHS – FT Date: 26 April 2017 NAME POSITION INTERESTS DECLARED Chris Hurst Non-Executive Non-Executive Director, Webmoco Ltd a – Director software development and design company (currently has no NHS clients) Independent Advisor, Philips Healthcare Incubator a new products division which is – developing home based monitoring and test technology, initially for use by patients undergoing chemotherapy (note: this is being developed in partnership with a number of NHS cancer centres and is not yet a
NAME POSITION INTERESTS DECLARED Dominic Hardisty Chief Operating Officer Wife is self-employed bid manager whose work includes writing bids for NHS and social care contract tenders for a variety of NHS, third sector and private sector providers. Very occasionally these might give rise to a conflict of interest relating to bids that the Trust intends making, in which case this would need to be specifically declared and appropriate arrangements made. Date: 21 June 2016 NAME POSITION INTERESTS DECLARED Martin Howell Chair Governor – Oxford Brookes University Governor – Oxford University Hospitals NHS FT Date: 26 April 2017 NAME POSITION INTERESTS DECLARED Chris Hurst Non-Executive Director Non-Executive Director, Webmoco Ltd – a software development and design company (currently has no NHS clients) Independent Advisor, Philips Healthcare Incubator – a new products division which is developing home based monitoring and test technology, initially for use by patients undergoing chemotherapy (note: this is being developed in partnership with a number of NHS cancer centres and is not yet a
61ii_Register_Directors_Interests_May-2018-v.2.docx